Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-α/Ribavirin

被引:26
作者
Amati, L
Caradonna, L
Magrone, T
Mastronardi, ML
Cuppone, R
Cozzolongo, R
Manghisi, OG
Caccavo, D
Amoroso, A
Jirillo, E
机构
[1] Sci Inst Digest Dis, Labs Immunopathol, Bari, Italy
[2] Sci Inst Digest Dis, Div Gastroenterol, Bari, Italy
[3] Univ Bari, Dept Internal Med Immunol & Infect Dis, Bari, Italy
[4] Univ Roma La Sapienza, Dept Clin Med, Rome, Italy
关键词
D O I
10.2174/1381612024607036
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The balance between T helper (h)(1) and Th-2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th-1 cytokines [interleukin (IL-2) and interferon (IFN-gamma)] have been demonstrated to mediate the antiviral immune response. Serum levels of Th-1 cytokines (IL-2 and IFN-gamma) as well as of Th-2 products (IL-4 and IL-10) were determined in a group of HCV-positive patients before and after treatment with IFN-alpha and Ribavirin (RIB). Results indicate that responder patients exhibited increased levels of IFN-gamma and IL-10, while this enhancement was not observed in non-responder patients. In this respect, the major effect exerted by the combined therapy with IFN-alpha/RIB could be represented by the attainment of a re-equilibrium between inflammatory (Th-1) and anti inflammatory (Th-2) mechanisms. In this framework, according to current literature, novel therapeutical approaches to treat HCV infection are represented by administration of recombinant IL-2 and IL-10.
引用
收藏
页码:981 / 993
页数:13
相关论文
共 76 条
[1]  
ALBER MS, 1997, PROG NONLIN, V26, P1
[2]   Cytokine and chemokine based control of HIV infection and replication [J].
Alfano, M ;
Poli, G .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (11) :993-1013
[3]   Nerve growth factor in neurological and non-neurological diseases: Basic findings and emerging pharmacological prospectives [J].
Aloe, L ;
Tirassa, P ;
Bracci-Laudiero, L .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (02) :113-123
[4]   In vitro effects of Naloxone on T-lymphocyte-dependent antibacterial activity in hepatitis C virus (HCV) infected patients and in inflammatory bowel disease (IBD) patients [J].
Amati, L ;
Caradonna, L ;
Magrone, T ;
Manghisi, C ;
Leandro, G ;
Caccavo, D ;
Covelli, V ;
Sciorsci, RL ;
Minoia, P ;
Jirillo, E .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2001, 23 (01) :1-11
[5]   Soluble HLA class I antigens in chronic hepatitis C: A disease-associated manifestation or molecules modulating immunoresponsiveness? [J].
Antonaci, S ;
Jirillo, E ;
Schiraldi, O .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1999, 21 (04) :727-738
[6]   Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial [J].
Bodenheimer, HC ;
Lindsay, KL ;
Davis, GL ;
Lewis, JH ;
Thung, SN ;
Seeff, LB .
HEPATOLOGY, 1997, 26 (02) :473-477
[7]   Pathogenesis, diagnosis and management of hepatitis C [J].
Boyer, N ;
Marcellin, P .
JOURNAL OF HEPATOLOGY, 2000, 32 :98-112
[8]   PILOT-STUDY OF COMBINATION THERAPY WITH RIBAVIRIN PLUS INTERFERON-ALFA FOR INTERFERON ALFA-RESISTANT CHRONIC HEPATITIS-C [J].
BRILLANTI, S ;
GARSON, J ;
FOLI, M ;
WHITBY, K ;
DEAVILLE, R ;
MASCI, C ;
MIGLIOLI, M ;
BARBARA, L .
GASTROENTEROLOGY, 1994, 107 (03) :812-817
[9]   GENETIC-HETEROGENEITY OF HEPATITIS-C VIRUS - QUASI-SPECIES AND GENOTYPES [J].
BUKH, J ;
MILLER, RH ;
PURCELL, RH .
SEMINARS IN LIVER DISEASE, 1995, 15 (01) :41-63
[10]  
BVEVEGNU L, 1997, HEPATOLOGY, V25, P211